Our Pricing

Buy Weight Loss Injections Online UK: GLP-1 Treatments from £135.00

Published on: June 03, 2026

When you buy weight loss injections online UK from Cured Pharmacy, you access genuine MHRA-licensed GLP-1 treatments including Mounjaro, Wegovy, and Saxenda, with transparent pricing from £135.00 and free clinical assessment by UK-registered prescribers. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures every prescription meets rigorous UK safety standards, with discreet next-day delivery available across the country.

How GLP-1 Weight Loss Injections Work

GLP-1 receptor agonists mimic naturally occurring incretin hormones that regulate appetite and blood glucose levels. These medications slow gastric emptying, enhance satiety signals to the brain, and reduce hunger between meals—mechanisms that support sustained weight reduction when combined with lifestyle modifications [1].

Mounjaro (tirzepatide) represents the latest advancement: a dual GIP/GLP-1 receptor agonist that activates two complementary metabolic pathways. In the SURMOUNT-1 trial, participants achieved an average 22.5% body weight reduction at the 15mg dose over 72 weeks—the highest efficacy demonstrated in obesity pharmacotherapy to date [1]. Wegovy (semaglutide) and Saxenda (liraglutide) work through single GLP-1 pathways, with the STEP trials showing average reductions of 14.9% and 5-7% respectively [2][3].

Mounjaro vs Wegovy vs Saxenda: Clinical Comparison

All three treatments are MHRA-licensed for chronic weight management in adults with a BMI ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidities, but they differ significantly in mechanism, dosing schedule, and clinical outcomes.

Mounjaro's dual-agonist mechanism typically produces greater weight reduction than single-pathway alternatives, though individual response varies based on metabolic factors, adherence, and baseline characteristics. Wegovy offers once-weekly convenience with well-established efficacy data across diverse populations. Saxenda requires daily administration but may suit patients who prefer gradual dose escalation or have specific contraindications to weekly formulations.

Your prescriber will assess your medical history, current medications, weight loss goals, and tolerance for injection frequency before recommending the most appropriate option. Factors including cardiovascular history, diabetic status, previous GLP-1 experience, and budget considerations all influence treatment selection.

Choosing Between Injectable and Oral Options

Wegovy Oral Tablets (semaglutide pill) offer an alternative for patients who prefer not to inject. While absorption differs from subcutaneous formulations, oral semaglutide provides comparable GLP-1 pathway activation with daily tablet administration. Clinical trials demonstrate efficacy, though weight reduction percentages typically fall between injectable semaglutide and liraglutide [4].

Orlistat-Based Treatments: Fat Absorption Blockers

Orlistat works through an entirely different mechanism: it inhibits pancreatic and gastric lipases, preventing approximately 30% of dietary fat absorption. Unlike GLP-1 agonists that regulate appetite centrally, orlistat acts locally in the gastrointestinal tract [5].

Available as prescription-strength Xenical (120mg) or lower-dose Alli and Orlos (60mg), orlistat suits patients who prefer oral capsules over injections or have contraindications to incretin-based therapies. Clinical trials show average weight loss of 5-10% when combined with a reduced-calorie, lower-fat diet, though efficacy depends heavily on dietary fat restriction [5].

Gastrointestinal side effects—including oily stools, increased bowel frequency, and faecal urgency—occur more frequently when dietary fat intake exceeds recommended levels. These effects actually reinforce dietary adherence, as patients learn to moderate fat consumption to minimise symptoms.

Prescription vs Over-the-Counter Orlistat

Xenical (120mg) requires prescription and clinical assessment, while Alli (60mg) is available for pharmacy sale under supervision. Both contain the same active ingredient at different strengths. Your prescriber will recommend the appropriate dose based on your BMI, weight loss history, and tolerance for potential gastrointestinal effects.

Buy Weight Loss Injections Online UK: The Assessment Process

All prescription weight loss medications at Cured Pharmacy require completion of a clinical questionnaire reviewed by UK-registered prescribers. This typically takes under three minutes and covers your medical history, current medications, cardiovascular health, endocrine conditions, and previous weight management attempts.

Our prescribers assess contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, and pregnancy or breastfeeding status. They also evaluate potential drug interactions, particularly with insulin, sulfonylureas, and medications affected by delayed gastric emptying.

If approved, your prescription is dispensed by our GPhC-registered pharmacy (9012511) and dispatched in 100% discreet packaging. We source only UK-licensed medicines through regulated wholesalers, ensuring authenticity and proper cold-chain management for temperature-sensitive injectables.

Transparent Pricing Before Consultation

Unlike many online services, Cured Pharmacy displays exact treatment costs before you begin your assessment. You'll see the complete price—including medication, prescriber review, and delivery—with no hidden consultation fees added at checkout. This transparency helps you make informed decisions about which treatment fits your budget and clinical needs.

Dosing Schedules and Titration Protocols

GLP-1 treatments follow gradual dose escalation protocols to minimise gastrointestinal side effects while optimising therapeutic response. Mounjaro typically starts at 2.5mg weekly for four weeks, increasing to 5mg, then potentially to 7.5mg, 10mg, 12.5mg, or 15mg based on tolerance and weight loss progress [1].

Wegovy begins at 0.25mg weekly, escalating monthly through 0.5mg, 1mg, 1.7mg, to a maintenance dose of 2.4mg. Saxenda requires daily titration from 0.6mg, increasing by 0.6mg increments every week until reaching the 3mg maintenance dose [2][3].

Your prescriber will provide detailed injection technique guidance, injection site rotation instructions, and advice on managing common side effects during titration. Most patients experience reduced nausea, constipation, or diarrhoea after the first few dose increases as their bodies adapt to higher GLP-1 levels.

Safety Monitoring and Long-Term Management

Weight loss medications require ongoing clinical oversight. Your prescriber will recommend regular follow-ups to assess treatment response, monitor for adverse effects, and adjust dosing as needed. Most patients see meaningful weight reduction within 12-16 weeks, with peak effects typically occurring between 52-72 weeks of continuous treatment [1][2].

Report any persistent nausea, vomiting, abdominal pain, or signs of pancreatitis (severe upper abdominal pain radiating to the back) immediately. While rare, serious adverse events require prompt medical evaluation. Your prescriber will also monitor for gallbladder disease, acute kidney injury in the context of dehydration, and hypoglycaemia if you're taking concurrent antidiabetic medications.

These treatments work best as part of comprehensive lifestyle modification including reduced-calorie nutrition, increased physical activity, and behavioural support. The medications facilitate adherence to these changes by reducing hunger and enhancing satiety, but they don't replace the fundamental principles of energy balance. Discontinuation typically leads to weight regain, so your prescriber will discuss long-term maintenance strategies tailored to your individual circumstances.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
4. Knop, F. K., Aroda, V. R., do Vale, R. D., et al. (2023). Oral Semaglutide 50 mg Taken Once per Day in Adults with Overweight or Obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 402(10403), 705–719. https://doi.org/10.1016/S0140-6736(23)01185-6 [accessed 13 August 2026]
5. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment, lifestyle modifications, and individual metabolic factors.